Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Onconetix, Inc. Director's Dealing 2025

Aug 19, 2025

35411_dirs_2025-08-19_10605409-1f7b-42b4-8b10-7c9e1fc91a6b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconetix, Inc. (ONCO)
CIK: 0001782107
Period of Report: 2025-08-15

Reporting Person: Oakley Andrew John (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-08-15 Common Stock J 20 Acquired 20 Direct
2025-08-15 Common Stock A 618 Acquired 638 Direct

Footnotes

F1: Represents a restricted stock award originally granted to the Reporting Person on March 23, 2025 pursuant to the Issuer's 2022 Equity Incentive Plan, as amended ("2022 Plan" and the grant on such date, the "Original Award"). On August 15, 2025, the Original Award was modified to change the vesting terms, such that the award, which was to vest in full on August 31, 2025, was changed to vest in full on August 31, 2026, so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Except as set forth herein, the Original Award remains unmodified.

F2: On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis.

F3: Represents a restricted stock award granted to the Reporting Person pursuant to the 2022 Plan. The award will vest in full on August 31, 2026 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date.